Panavance Therapeutics Inc. is a privately held, clinical-stage pharmaceutical company developing a novel oncology asset, misetionamide (known as GP-2250). Panavance was formed in 2021 as a carve out of the Geistlich group, a family-owned Swiss company, to focus on GP-2250. Misetionamide is a tumor cell selective and broadly active small molecule with a unique dual mechanism of action which selectively disrupts the energy metabolism of cancer cells leading to cancer cell death as well as impacts nuclear factor-κB (“NFκB”) to affect cancer cells’ ability for protein synthesis and DNA transcription thereby restricting cancer cell growth and proliferation. The Company is advancing towards two registration directed clinical studies: a Phase 2/3 for the treatment of ovarian cancer and a Phase 3 trial as a first-line maintenance in pancreatic cancer. Extensive preclinical studies have demonstrated that GP-2250’s broadly anti-neoplastic MOA has the potential to be effective in many cancers.